Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH Personnel And Related Costs — Research And Development Expense

Other product segments

Share Based Compensation Expense
$4.85M—
Other Costs
$1.49M+25.5%
Discovery Expenses
$1.36M+51.4%

Similar metrics at other companies

Tango Therapeutics logo
TNGXPersonnel-Related Expenses-RD — Research And Development Expense
$12.93M-6.6%
Tango Therapeutics logo
TNGXFacilities And Other Related Expenses-RD — Research And Development Expense
$4.34M-20.6%
Cogent Biosciences, Inc. logo
COGTResearch And Development Personnel Related — Operating Income
$18.05M+21.3%
Scholar Rock logo
SRRKEarly Research — Research And Development Expense
$1.21M-16.8%
Scholar Rock logo
SRRKRD Expense Srk439 — Research And Development Expense
$1.76M-58.9%
ACI Worldwide logo
ACIWResearch and Development Expense, Software (Excluding Acquired in Process Cost)
$44.09M+13.3%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%
Enterprise value$3.88B+565%
P/S1,465.1×+962×

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's personnel and related costs — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's personnel and related costs — research and development expense?
Dianthus Therapeutics (DNTH) reported personnel and related costs — research and development expense of $8.64M in Q1 2026.
How has Dianthus Therapeutics's personnel and related costs — research and development expense changed year-over-year?
Dianthus Therapeutics's personnel and related costs — research and development expense increased by 47.7% year-over-year, from $5.85M to $8.64M.
What does personnel and related costs — research and development expense mean?
This metric represents the portion of total research and development expenditures specifically allocated to compensation, benefits, and related personnel costs for scientific and clinical staff. It reflects the company's investment in human capital dedicated to advancing its drug pipeline and clinical trial programs. Monitoring this figure helps investors assess the company's commitment to innovation and the intensity of its internal research capabilities.